BOSTON, Nov. 4, 2021 /PRNewswire/ -- GreenLight
Biosciences is delighted to announce the appointment of Professor
Diane E. Griffin, MD, PhD, and
Emmanuel Hanon, DVM, PhD, to its
Human Health Scientific Advisory Board.
At Johns Hopkins University,
Diane Griffin is the Distinguished
Service Professor, a professor of Medicine and Neurology at the
School of Medicine, and the W. Harry
Feinstone professor at the Department of Molecular
Microbiology and Immunology at the Bloomberg School of Public
Health. She has also been vice president of the U.S. National
Academy of Sciences since 2013. Professor Griffin brings the
experience of a distinguished career to facilitate the R&D work
of GreenLight, especially her focus on pathogenesis of acute RNA
virus infections and the role of the immune response in virus
clearance, protection from infection, and mechanisms of
vaccine-induced protection.
Emmanuel Hanon's 20-year career
at GlaxoSmithKline included 7 years as the GSK Vaccines' senior
vice president and head of R&D. As a virologist and
immunologist, he made critical contributions to next-generation
adjuvants and their inclusion in successful vaccines for pandemic
influenza, malaria, and shingles. He currently serves as head of
R&D for Viome, a precision medicine company focusing on chronic
disorders. Dr. Hanon's experience in vaccinology and product
development will be critical in helping GreenLight accelerate its
development programs.
Amin Khan, GreenLight's Human
Health chief scientific officer, said: "GreenLight aims to solve
some of the world's biggest problems by delivering on the full
potential of RNA, including producing vaccines and gene therapies.
We're delighted that Diane and Emmanuel have joined our Scientific
Advisory Board. Their expertise in virology, immunology, public
health, and product development will help us accelerate our
progress."
About GreenLight Biosciences, Inc.
Founded in 2008,
GreenLight's aims to solve some of the world's biggest problems by
delivering on the full potential of RNA for human health and
agriculture.
In human health, this includes mRNA vaccines and therapeutics.
In agriculture, this includes RNA to protect honeybees and a range
of crops. The company's breakthrough cell-free RNA manufacturing
platform, which is protected by numerous patents, allows for
cost-effective and scalable production of RNA. For more
information, visit https://www.greenlightbiosciences.com/
In August 2021, GreenLight
Biosciences announced plans to become publicly listed through a
business combination with Environmental Impact Acquisition Corp.
(NASDAQ: ENVI).
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995, with respect to the
proposed transaction between GreenLight Biosciences, Inc.
("GreenLight") and Environmental Impact Acquisition Corp. ("ENVI").
These forward-looking statements generally are identified by the
words "believe," "project," "expect," "anticipate," "estimate,"
"intend," "strategy," "future," "opportunity," "plan," "may,"
"should," "will," "would," "will be," "will continue," "will likely
result" and similar expressions. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including but not limited to the
risk that the transaction may not be completed in a timely manner
or at all, which may adversely affect the price of ENVI's
securities and the effect of the announcement or pendency of the
transaction on GreenLight's business relationships, operating
results, and business generally. Forward-looking statements speak
only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and ENVI and
GreenLight assume no obligation and do not intend to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/greenlight-biosciences-envi-adds-two-world-renowned-scientists-to-its-scientific-advisory-board-301416685.html
SOURCE GreenLight Biosciences, Inc.
